# Universitat de Vic - Universitat Central de Catalunya

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/universitat-de-vic-universitat-central-de-catalunya/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 88.1 |
| Citations | 250,798 |
| City | Vic |
| Country | ES |
| Description | Universitat de Vic - Universitat Central de Catalunya is a research organisation in Vic, ES. OpenAlex records 9,771 works and 250,798 citations for it. 1,831 researchers list it as their most recent affiliation. |
| Homepage | http://www.uvic-ucc.cat/en |
| OpenAlex ID | https://openalex.org/I115304662 |
| Researchers | 1,831 |
| ROR ID | https://ror.org/006zjws59 |
| Type | education |
| Wikidata ID | https://www.wikidata.org/wiki/Q935460 |
| Works | 9,771 |

## University papers

Showing 12 of 47.

- [The mutational constraint spectrum quantified from variation in 141,456 humans](https://scholariq.org/papers/the-mutational-constraint-spectrum-quantified-from-variation-in-141-456-humans/)
- [2019 ESC/EAS Guidelines for the management of dyslipidaemias: <i>lipid modification to reduce cardiovascular risk</i>](https://scholariq.org/papers/2019-esc-eas-guidelines-for-the-management-of-dyslipidaemias-i-lipid/)
- [2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk](https://scholariq.org/papers/2019-esc-eas-guidelines-for-the-management-of-dyslipidaemias-lipid-modification/)
- [2014 ESC/EACTS Guidelines on myocardial revascularization](https://scholariq.org/papers/2014-esc-eacts-guidelines-on-myocardial-revascularization/)
- [Defining the clinical course of multiple sclerosis](https://scholariq.org/papers/defining-the-clinical-course-of-multiple-sclerosis/)
- [Atherosclerosis](https://scholariq.org/papers/atherosclerosis/)
- [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS](https://scholariq.org/papers/2017-esc-focused-update-on-dual-antiplatelet-therapy-in-coronary-artery-disease/)
- [Autoantibodies against type I IFNs in patients with life-threatening COVID-19](https://scholariq.org/papers/autoantibodies-against-type-i-ifns-in-patients-with-life-threatening-covid-19/)
- [Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis](https://scholariq.org/papers/genetic-risk-and-a-primary-role-for-cell-mediated-immune-mechanisms-in-multiple/)
- [2015 ESC Guidelines for the diagnosis and management of pericardial diseases](https://scholariq.org/papers/2015-esc-guidelines-for-the-diagnosis-and-management-of-pericardial-diseases/)
- [ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD](https://scholariq.org/papers/esc-guidelines-on-diabetes-pre-diabetes-and-cardiovascular-diseases-developed-in/)
- [Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease](https://scholariq.org/papers/large-scale-association-analysis-identifies-13-new-susceptibility-loci-for/)

## University top topics

Showing 8 of 23.

- [HIV Research and Treatment](https://scholariq.org/topics/hiv-research-and-treatment/)
- [SARS-CoV-2 and COVID-19 Research](https://scholariq.org/topics/sars-cov-2-and-covid-19-research/)
- [HIV/AIDS drug development and treatment](https://scholariq.org/topics/hiv-aids-drug-development-and-treatment/)
- [Physical Activity and Health](https://scholariq.org/topics/physical-activity-and-health/)
- [Sports Performance and Training](https://scholariq.org/topics/sports-performance-and-training/)
- [Sports injuries and prevention](https://scholariq.org/topics/sports-injuries-and-prevention/)
- [COVID-19 Clinical Research Studies](https://scholariq.org/topics/covid-19-clinical-research-studies/)
- [Frailty in Older Adults](https://scholariq.org/topics/frailty-in-older-adults/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.